Doprid

Quick links to important sections

Doprid

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doprid

Property Description
Active ingredient Sulpiride (INN)
Form Tablets, Capsules, Injectable Solution
Pharmacological class Antipsychotic Agent (Neuroleptic)
General purpose Stabilizing thought and mood processes
Origin Synthetic substituted benzamide derivative

Defining the Substance and Entity

Doprid is a prescription-only medicinal product whose primary active ingredient is Sulpiride (INN). Chemically, Sulpiride is a synthetic compound classified as a substituted benzamide derivative, defining its core structural group. This formulation is a single-entity product, containing only Sulpiride combined with pharmaceutical excipients. Doprid is available in several dosage forms, including solid oral forms such as tablets and capsules, alongside aqueous injectable solutions for parenteral administration.

Classification as an Antipsychotic Agent

Doprid belongs to the pharmacological class of antipsychotic agents, which are broadly known as neuroleptics, reflecting their modulatory effect on the central nervous system. Its placement within the World Health Organization's Anatomical Therapeutic Chemical (ATC) index as N05AL01 designates its classification as a Benzamide-type antipsychotic.

Sulpiride is distinguished as a selective dopamine receptor antagonist primarily targeting the D2 and D3 subtypes. This focused profile is clinically recognized for giving the compound atypical antipsychotic characteristics, differentiating it from older, less selective neuroleptics.

The General Purpose of Doprid (Sulpiride)

The general purpose of Doprid is to provide a stabilizing influence on specific neural circuits in the brain, thereby managing severe disturbances in thought and emotional processing. This stabilization is achieved by the compound's effect of rebalancing the activity of the brain’s dopamine system. The dual nature of its selective mechanism means the drug aims to restore a more balanced mental state, relevant for reducing the severity of disturbed thinking associated with psychosis. Due to its concentration-dependent activity, the medication also serves a recognized role by providing a mood-elevating component, making it applicable in addressing specific emotional and motivational deficits characteristic of major depressive disorder.

What side effects are possible with Doprid?

Possible Side Effects and Safety Information

The official safety profile for Doprid (Sulpiride) details potential adverse reactions categorized by frequency and the body system affected, according to regulatory standards like those established by the EMA and national health authorities.

Common Adverse Reactions (Occurring in at least 1 in 100 people) often involve the endocrine and nervous systems. These frequently reported effects include hyperprolactinaemia (increased prolactin levels), weight gain, sedation or drowsiness, insomnia, and movement disorders classified as extrapyramidal symptoms (such as tremor and parkinsonism).

Serious Adverse Reactions are explicitly documented by regulators, highlighting clinically critical events regardless of their rare occurrence. These include the potential for Neuroleptic Malignant Syndrome (NMS), severe cardiovascular risks like Torsade de Pointes and cardiac arrest, and the risk of Venous Thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism.

Population and Duration Safety Notes

Official labels define specific considerations for certain patient groups. Older adults may have increased susceptibility to effects like postural hypotension and require cautious monitoring. Patients with renal impairment necessitate dose reduction, as Sulpiride is primarily eliminated by the kidneys. Furthermore, the development of Tardive Dyskinesia, characterized by involuntary movements, is associated with long-term exposure to the medicine, typically administration exceeding three months.

Official regulatory restrictions, such as contraindications, prohibit use in patients with pre-existing prolactin-dependent tumors (e.g., breast cancer) or phaeochromocytoma.

Overdose and Emergency Response

Overdose and when to seek help

Any suspected overdose of Doprid (Sulpiride) requires the patient to seek immediate medical attention and go to a hospital casualty department straight away. This urgent action is mandated due to the potential for severe, life-threatening outcomes documented in regulatory prescribing information.

Documented Clinical Manifestations

Overdose manifestations primarily involve the Central Nervous System and motor function. These may include a reduced level of consciousness, pronounced drowsiness, confusion, agitation, and restlessness, with a potential progression to coma. Motor effects documented are severe extrapyramidal disorders, encompassing muscle stiffness, spasms, uncontrolled movements, and dystonic crises like torticollis (twisted neck) and trismus (lockjaw). The cardiovascular system may exhibit hypotension (low blood pressure).

Severe and Life-Threatening Outcomes

Official labeling specifies that overdose carries a risk of serious cardiovascular events, notably QT interval prolongation and severe ventricular arrhythmias such as Torsade de pointes, which can rapidly lead to cardiac arrest and sudden death. The potentially fatal complication Neuroleptic Malignant Syndrome (NMS) is also documented as a risk.

Management and Monitoring

No specific antidote is documented for Doprid overdose. Treatment is officially designated as strictly symptomatic and supportive. Following exposure, close monitoring is required, specifically to observe for signs of long QT syndrome and severe arrhythmias. Anticholinergic drugs are described as a procedural measure to manage the resulting extrapyramidal reactions.

Therapeutic Uses of Doprid

Doprid (Sulpiride): Main Uses and Therapeutic Benefits

Doprid is generally used in situations involving certain distressing symptoms across several key clinical domains. Its applications are relevant in contexts marked by increased discomfort or tension, particularly in managing complex symptom patterns. The medication is commonly used across conditions presenting with acute or chronic schizophrenia, major depressive disorder, and for specialized symptom management like severe vertigo and motor tics.

It is applied in clinical settings that involve acute or unstable symptom patterns, supporting patients who experience significant disturbances in thought, mood, or behavior. “The medication is relevant in contexts involving heightened systemic burden, offering supportive relief when symptoms interfere with routine activities.”

By helping to address symptom clusters that may become intense or disruptive, Doprid contributes to easing the overall symptom load during symptomatic periods. It is considered relevant for managing both the prominent thought disturbances and the chronic motivational deficits that complicate recovery.


Quick Fact: Relief for Complex Symptom Patterns Doprid is used for managing symptoms related to severe thought disorders, mood deficits, and specific functional issues like vertigo, supports maintenance of functional stability across multiple domains simultaneously.


Regulatory References

  1. Summary of Product Characteristics from the Irish Health Products Regulatory Authority

Eligibility and Restrictions for Use

Who Can and Cannot Use Doprid?

The official eligibility for using Doprid (Sulpiride) is strictly defined by regulatory documents, distinguishing between populations permitted use, those restricted, and those absolutely prohibited (contraindicated).


Eligibility Status and Restrictions

Population Group Regulatory Status
Phaeochromocytoma Contraindicated (Must not use)
Prolactin-dependent tumours Contraindicated (Must not use)
Adults Allowed (Standard Labeled Conditions)
Children under 14 years Not Recommended (Insufficient experience)
Pregnant women Not Recommended (Should be avoided)
Lactating women Not Recommended (Should be avoided)
Severe Renal Impairment Conditional Use (Requires dose reduction)

Use is also contraindicated in patients with Acute Porphyria or known hypersensitivity to Sulpiride. The combination of Doprid with Levodopa or specified antiparkinsonian drugs is also prohibited by regulatory labeling. Older adults and patients with a history of epilepsy or cardiovascular risk factors are defined as populations requiring particular caution during use.

What should I know about interactions with other medicines?

Doprid Interactions with other medicines and products

Official regulatory documents define the interaction profile of Doprid (Sulpiride) based on pharmacodynamic antagonism, additive effects, and specific pharmacokinetic interference.


Contraindicated and Non-Recommended Combinations

Interaction Type Interacting Agent Official Regulatory Status
Pharmacodynamic Antagonism Levodopa and certain dopaminergic agonists (e.g., Ropinirole) Contraindicated
Additive Cardiovascular Risk Drugs that prolong the QT interval (e.g., Amiodarone, Haloperidol, Quinidine) or induce bradycardia Not Recommended

Other Documented Interaction Constraints

Co-administration with agents that depress the central nervous system (e.g., benzodiazepines, narcotics, and Alcohol) leads to an enhanced sedative effect. The co-use of Antacids or Sucralfate is documented to cause a decreased absorption of Sulpiride, necessitating an administration timing rule. To restore bioavailability, Sulpiride must be taken at least 2 hours before these specific agents. Electrolyte imbalances, such as hypokalaemia, must be corrected before using QT-prolonging combinations, as this condition potentiates the interaction risk. Furthermore, regulatory sources note that Sulpiride neither inhibits nor stimulates CYP450 enzymes, indicating no clinically significant CYP-mediated interactions.

Mechanism of Action

Selective Modulation of Dopamine Receptors

This domain centers on the drug’s primary action as a selective antagonist of the Dopamine D2 and D3 receptors within the central nervous system. This direct interruption of dopamine signal transduction in the mesolimbic pathway functionally results in the reduction of excessive signal transduction within the pathway. The compound exhibits minimal affinity for other common neurotransmitter receptors (like serotonin or histamine), restricting its mechanistic action to the dopaminergic system.

Dual-Action Mechanistic Cascade

The mechanism is defined by a concentration-dependent dual action. At relatively low concentrations, the molecule preferentially blocks presynaptic autoreceptors, eliminating an inhibitory feedback mechanism and enhancing dopamine release. At higher concentrations, the mechanism is dominated by the blocking of postsynaptic receptors, directly suppressing the signal. This capability to functionally regulate both the release and postsynaptic effects of dopamine allows for a dual-directional modulation of dopaminergic tone.

Systemic Pathway Influence

This mechanism extends beyond core signaling to influence the tuberoinfundibular tract. Antagonism of D2 receptors in the pituitary gland removes the normal inhibitory control over hormone release. This physiological consequence leads directly to elevated prolactin concentrations in the bloodstream, reflecting the drug's effect on the neuroendocrine axis.

Dosage and Administration Information

How Doprid (Sulpiride) is Used: Official Administration Guidelines

Doprid (Sulpiride) is administered according to guidelines that define the approved routes, standard dosing schedules, and adjustments for specific patient groups to ensure procedural consistency.


Administration Routes and Dosing Patterns

The primary method of use is the oral route, via tablets, capsules, or oral solution. The intramuscular (IM) injection route is reserved for short-term, acute clinical situations requiring rapid stabilization and is intended to be replaced by oral therapy promptly.

For maintenance treatment, the medicine is typically administered in divided doses twice daily, often taken in the morning and early evening. This frequency pattern is designed to maintain consistent systemic levels throughout the day.


Standard Dosing and Timing

The standard adult starting dose generally falls within the range of 400 mg to 800 mg daily. Maintenance doses are adjusted individually, but the maximum recognized daily dose is 2400 mg per day (administered as 1200 mg twice daily).

In terms of timing, the tablets must be swallowed whole with water. A critical instruction involves co-administration: Doprid must be taken at least two hours before antacids or sucralfate to prevent decreased absorption and ensure the intended amount of medicine is processed by the body.


Population-Specific Adjustments

Official instructions mandate dose modifications for certain populations, reflecting the medicine’s primary route of elimination.

Population Group Procedural Instruction
Renal Impairment Dose must be reduced and/or the interval between doses increased proportional to the degree of kidney function decline (e.g., half dose for Cl cr 30–60 mL/min).
Older Adults The dose must be reduced if any degree of renal impairment is present.
Pediatric Patients Not generally recommended for use in children under 14 years of age due to limited clinical experience and recommendations in many regions.

Recent Clinical Evidence

Research evidence / Overview of Studies for Doprid (Sulpiride)


Evidence for Use in Schizophrenia

The clinical evaluation of Sulpiride for use in acute and chronic schizophrenia was explored primarily in short-term Randomized Controlled Trials ( RCTs). Research explored how symptoms change over time and also compared Sulpiride against both a placebo (inactive substance) and various other antipsychotic medications. Studies monitored outcomes related to symptom intensity or variability, with particular focus on the measurement of both positive symptoms (e.g., disturbances in thought) and negative symptoms (e.g., emotional withdrawal or apathy).

Findings describe patterns observed in the studies related to measurements taken of overall global clinical state and symptom measurement results in the observed populations during the short-term treatment period. Comparative trials reported measurements that showed patterns related to trial endpoints when Sulpiride was evaluated against other compounds. Research describes symptom patterns, particularly during periods of increased symptom activity.


Evidence for Use in Major Depressive Disorder

Research explored the potential use of Sulpiride in major depressive disorder ( MDD). Studies were conducted to explore short-term symptom changes, often comparing Sulpiride against older classes of antidepressant medications or observing it as an adjunctive agent (used in combination with a primary antidepressant). Key outcomes included the measurement of depressive symptom scores and assessed how patients reported their experience related to specific mood and activating effects.

Research highlights changes measured during the study period, with findings describe patterns where changes in measured depressive symptom scores were observed in some studies. The research provides context but not individual predictions, especially since comparative evidence is lacking against the most modern, widely used antidepressant drug classes. Existing evidence is limited, as the research primarily focuses on short-term symptom relief, typically over a period of four to eight weeks.


Long-Term Studies and Follow-up Durations

Research examined short-term measured outcomes across all primary indications for Doprid, with initial RCTs generally having follow-up durations limited to around three months. Studies provide insight into short-term measured outcomes; however, data are still emerging regarding sustained functional outcomes.

Scientific reviews indicate that robust, high-quality research specifically focused on long-term effects are not fully established regarding extended-duration measured stability or the frequency of symptom return over periods exceeding one year. There is limited information for long-term outcomes, and research is ongoing in this area to better understand long-term patterns.

Frequently Asked Questions (FAQ)

Common questions about Doprid (FAQ)


Q: Is Doprid generally used for a short time or for long-term treatment?

According to official product information, treatment with this medication is typically for the long term, particularly if it is shown to be effective. Official guidelines describe continued use unless adjusted by a prescriber. It should be noted that the regulatory documents describe certain risks, like Tardive Dyskinesia, that are associated with extended periods of use.


Q: Is Doprid considered a controlled substance or scheduled drug?

Regulatory documents classify the active substance in Doprid as a 'Prescription Only Medicine' (POM) in many jurisdictions. This classification confirms that the drug can only be dispensed under the direct authority of a licensed prescriber, reflecting its controlled nature as a pharmaceutical agent.


Q: Does Doprid work immediately, or does it build up in the system?

The active substance has an elimination half-life of approximately 8 hours. This means the medicine is cleared from the body over a period of 32 to 40 hours. The pattern of elimination and administration suggests the medication builds up to maintain a consistent level in the body over time, though initial effects may be noticed earlier.


Q: Does taking Doprid with food or on an empty stomach make a difference to its effect?

Official administration instructions indicate that the tablets can be taken either before or after meals. However, regulatory documents specify that Doprid should be taken at least two hours before antacid remedies or sucralfate to ensure the body absorbs the intended amount of medicine.


Q: Are there any non-prescription medications that are known to interact with Doprid?

Yes, regulatory documents describe specific interactions, particularly with over-the-counter remedies like antacids. Antacid remedies for indigestion can reduce the absorption of the medication into the bloodstream, due to a documented administration timing rule for co-administration. Combining this medicine with any central nervous system depressants, whether prescribed or not, may also increase the risk or severity of effects like sedation.


Q: Can certain vitamins or herbal supplements affect how Doprid works?

Official product information describes the need for a healthcare professional to be aware of any over-the-counter medicines or herbal remedies being taken, as this helps prevent unknown or unexpected interactions that could affect how the medication works or increase the risk of side effects.


Q: Is it normal to feel dizzy or drowsy when first starting Doprid?

Drowsiness and sedation are listed in the official documents as common side effects. While dizziness is not listed as common, it can be a general effect of CNS-acting drugs. The product information notes that some side effects are observed to lessen over time.


Q: Do the common digestive side effects of Doprid usually go away over time?

Constipation is documented as a common gastrointestinal side effect of this medication. Regulatory documents generally describe that some side effects are observed to lessen over time, although specific duration for constipation is not given.


Q: Is a skin rash a known side effect of Doprid?

Yes, according to the official safety profile, a maculo-papular rash has been reported as a common side effect. Unexpected skin reactions are important to report to a healthcare professional.


Q: How often are liver function tests mentioned as monitoring when taking Doprid?

Tests may be required to check that liver and kidney function have not been affected by the medicine. Monitoring may be advised because the drug is eliminated primarily by the kidneys, and official guidance for dose adjustment is based on kidney function.


Q: Do people with multiple medications face a higher risk when taking Doprid?

Official product information highlights that combining Doprid with various other drugs can increase the risk or severity of adverse effects, including combined use with CNS depressants. The specific interaction profile is important to review with a prescriber when taking multiple medications.


Q: Is it safe to drive or operate heavy machinery while using Doprid?

Official patient information states that the medication can affect the ability to perform skilled tasks such as driving or operating heavy machinery. This is due to the potential for side effects like drowsiness and sedation.


Q: What is the risk of dependence or withdrawal associated with Doprid?

Official documentation notes that suddenly stopping the medication may cause withdrawal symptoms. These symptoms may include anxiety, tremor, difficulty sleeping, nausea, and vomiting.


Q: If a person misses a dose of Doprid, what general guidance is provided in the documentation?

The general guidance in the product documentation is to skip the missed dose and resume the normal dosing schedule at the next scheduled time. Taking a double dose to compensate is not advised in the documentation.


Q: What information does the official documentation provide regarding overdose of Doprid?

Official documentation outlines the symptoms that may occur in the event of an overdose. These symptoms can include agitation, confusion, uncontrollable movements, low blood pressure, and coma.


Q: Have there been any major updates or safety warnings issued for Doprid recently?

Official regulatory documents, such as the Summary of Product Characteristics (SmPC), are routinely updated to reflect new safety warnings. Recent updates have included warnings related to specific risks like Venous Thromboembolism (VTE) and blood disorders.


Q: Does Doprid cause 'brain fog' or affect concentration?

The official side effect profile documents common effects like sedation and drowsiness, which can interfere with mental clarity. Furthermore, the adverse reaction list includes 'confusion' as a reported effect, which addresses the intent of 'brain fog' or changes in concentration.


Q: Can Doprid affect fertility in men or women?

Official documents note that a decrease in fertility was observed in treated animals. This effect is linked to the drug's pharmacological effects on prolactin levels and is included as part of the safety profile.


Q: Does Doprid have a Black Box Warning from the FDA?

Official product information contains serious warnings documented in the Summary of Product Characteristics, which include increased mortality risk in elderly patients with dementia-related psychosis, Neuroleptic Malignant Syndrome (NMS), and Venous Thromboembolism (VTE). These are presented as major safety warnings for the medication.

How should Doprid be stored and disposed of?

Storage Requirements

Doprid (Sulpiride) must be stored at or below 25°C and protected from both light and moisture. The product must not be stored in a refrigerator or freezer. To maintain quality, the medicine must be kept in its original container until use. All forms of this medication must be kept securely out of the sight and reach of children.

Disposal Instructions

Unused or expired Doprid must not be disposed of using wastewater or household trash. The official requirement is to return the unused product to a pharmacy or a designated community waste disposal scheme for proper pharmaceutical waste handling, according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doprid found in:

A-Z Index: